Last edition
News about Global Pharma
Artemis Acquires Millrock Technology
Under Artemis' ownership, Millrock will continue to operate as an independent company from its facility in Kingston, New York, serving a global customer base.
Global Pharma | 01/10/2025 | By Dineshwori | 339
AbbVie has begun a USD 70 million expansion of its AbbVie Bioresearch Center (ABC) in Worcester, Massachusetts, and broken ground on a new North Chicago Active Pharmaceutical Ingredient (API) manufacturing facility.
Global Pharma | 01/10/2025 | By Dineshwori | 318
Pfizer signs Agreement with US Government to Lower Drug Costs for American Patients
Pfizer has voluntarily agreed to implement measures designed to ensure Americans receive comparable drug prices to those available in other developed countries and pricing newly launched medicines at parity with other key developed markets.
Global Pharma | 01/10/2025 | By Dineshwori | 293
Biocon Biologics, Amgen Settle Patent Dispute, Paving Way for US Launch of Denosumab Biosimilars
The agreement with Amgen enables Biocon Biologics to launch denosumab biosimilars Bosaya and Aukelso in the US from October 1, 2025.
Global Pharma | 01/10/2025 | By Dineshwori | 431
Lupin Receives Approval from US FDA for Rivaroxaban for Oral Suspension
Lupin’s Rivaroxaban will be manufactured at the company’s Chhatrapati Sambhajinagar facility.
Global Pharma | 01/10/2025 | By Dineshwori | 348
Nyxoah Expands Its Presence in Middle East
Nyxoah expands in the Middle East (ME) with new centres in Dubai, Kuwait and Abu Dhabi after the first Genio implant.
Global Pharma | 30/09/2025 | By Dineshwori | 205
Kai Beckmann to Lead Merck as CEO and Executive Board Chair
The Board of Partners of E. Merck KG appointed Kai Beckmann as future Chairman of the Executive Board and CEO of Merck. Belén Garijo’s tenure to be completed as planned by end of April 2026.
Global Pharma | 30/09/2025 | By Dineshwori | 314
Lupin Acquires VISUfarma, Strengthens Global Specialty Ophthalmology Business
By integrating VISUfarma’s established commercial operations, Lupin aims to tap into the attractive ophthalmology market.
Global Pharma | 30/09/2025 | By Dineshwori | 211
USA Tariff Policy Puts USD 3.1 Billion of Singapore Pharma Exports at Risk Amid Ongoing Talks
The USA’s new tariff policy threatens approximately USD 3.1 billion worth of Singapore’s pharmaceutical exports, according to Singaporean authorities, with trade discussions between the two nations currently underway.
Global Pharma | 29/09/2025 | By Darshana | 330
Dr. Reddy's, Hetero to Produce Affordable Generic Lenacapavir For HIV Prevention by 2027
Indian pharmaceutical companies Dr. Reddy’s Laboratories and Hetero Labs (Hetero) have signed landmark agreements to manufacture generic versions of lenacapavir, a revolutionary long-acting HIV prevention drug, which will be available at roughly USD 40 per patient per year in low- and middle-income countries (LMICs) starting in 2027.
Global Pharma | 29/09/2025 | By Dineshwori | 908
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy